12 Health Care Stocks Moving In Monday's Pre-Market Session
GRI Bio Inc GRI
$1.38
▼ -2.13%
($-0.03)
🎈 Low Float
🗓️ Earnings Next Week
Open
$1.47
Prev Close
$1.41
Day Range
$1.36 – $1.47
52W Range
$1.36 – $80.36
Market Cap
$2.44M
Beta
-1.31
EPS (TTM)
$-87.47
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-10 |
| Shares Out. | 1,770,000 |
| Website | gribio.com/ ↗ |
| Phone | 16194001171 |
| Employees | 5 |
| Net Income | -$2.0M |
| Free Cash Flow | -$12.1M |
| Total Assets | $11.3M |
| Total Liabilities | $794,000 |
| Equity | $10.5M |
About GRI Bio Inc
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
GRI Bio Inc is a publicly traded company under the ticker symbol GRI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)